For most of human history, aging was accepted as inevitable. That is starting to change. Over the past two decades, research into the biology of aging has accelerated to a degree that would have seemed implausible a generation ago. Scientists now have a clearer picture of what aging does at the cellular level, and with that picture has come a growing toolkit of strategies aimed at slowing it down.
A sweeping review published in ACS Chemical Neuroscience, drawing on data from the CAS Content Collection, one of the largest compiled databases of scientific literature, mapped the current landscape of antiaging research across geographies, disciplines, and drug development pipelines. What it found is a field that has moved well past speculation.
What aging actually does to the body
Aging is not a single event. At the molecular level it involves DNA damage, telomere shortening, protein aggregation, and the accumulation of dysfunctional cellular components. At the cellular level it shows up as senescence, stem cell exhaustion, impaired nutrient sensing, and low-grade chronic inflammation. These processes do not happen independently. They compound each other, which is part of why age-related diseases including Alzheimer’s, cardiovascular disorders, and cancer effectively double in incidence every five years after age 60.
More than 2 billion people are expected to be over 60 by 2050. The medical and economic implications of that demographic shift are driving a significant amount of the current urgency in aging research.
Antiaging strategies drawing the most attention
Physical exercise ranks as the most studied antiaging intervention in the scientific literature, and the evidence behind it is substantial. Regular activity in older adults helps preserve muscle mass, supports cardiovascular and respiratory function, maintains cognitive performance, and operates at the cellular level by protecting telomere length and reducing markers of cellular senescence. Exercise also appears to stimulate neurogenesis in the hippocampus, the brain region most associated with memory.
Caloric restriction has shown the greatest measurable impact on lifespan extension across species, with reductions of 10 to 30% in caloric intake linked to longer and healthier lives in multiple animal models. Because sustained caloric restriction is difficult for most people to maintain, researchers have focused on compounds that mimic its biological effects. Rapamycin, metformin, and resveratrol are among the most studied of these caloric restriction mimetics, with animal studies showing lifespan extensions of up to 25 to 30%.
Emerging antiaging frontiers
Parabiosis, the infusion of young blood plasma into older subjects, has attracted growing scientific attention. Animal studies have shown that circulating factors in young blood can reverse age-related decline by targeting several aging hallmarks including stem cell exhaustion and chronic inflammation. A clinical trial run by the company Alkahest explored the safety and feasibility of young plasma infusions in patients with mild to moderate Alzheimer’s disease and found the treatment to be safe and tolerable, though researchers noted the need for larger controlled trials.
Senotherapy is another area gaining traction. This approach targets senescent cells directly, either by eliminating them using drugs called senolytics or by suppressing the inflammatory proteins they secrete. Unlike many antiaging interventions, senolytics appear effective when administered intermittently rather than continuously, which makes them more practical as a potential treatment.
Gut microbiota research has also entered the antiaging conversation. Studies have found that longevity correlates with specific bacterial changes in the gut, and that microbiota-targeted interventions including probiotics, prebiotics, and fecal transplantation show promise not only for age-related diseases but for slowing the aging process itself. Animal studies found that transferring microbiota from young donors into older animals reversed certain inflammation-related changes in the brain and retina.
What the antiaging drug pipeline looks like
A new branch of medicine called geroscience has emerged around the idea that targeting the aging process itself is more efficient than treating individual age-related diseases after they develop. Researchers are examining existing approved drugs for antiaging potential, including aspirin, metformin, melatonin, and certain statins. The appeal of repurposing existing medications is that their long-term safety profiles are already established.
Natural compounds dominate the current pool of antiaging candidates. Vitamins, minerals, polyphenols, omega-3 fatty acids, and plant extracts including green tea, turmeric, and resveratrol all appear in the research literature with varying levels of supporting evidence. Vitamin D in particular has drawn clinical interest for its potential role in reducing oxidative stress, supporting DNA repair, and extending telomerase activity.
The science is not finished. Most antiaging research still takes place in non-human systems, and translating findings from animal models to human applications remains one of the field’s central challenges. But the direction of the research is clear, and the pace of it is accelerating.
